Ravi Rao
Director/Board Member chez DBV TECHNOLOGIES
Fortune : 9 828 $ au 31/03/2024
Profil
Le Dr Ravi M. Rao est médecin en chef chez Swedish Orphan Biovitrum AB et membre du Royal College of Physicians. Il est membre du conseil d'administration de DBV Technologies SA. Auparavant, le Dr Rao a été employé comme directeur médical chez Aeglea Biotherapeutics, Inc. et comme responsable des affaires médicales mondiales chez GlaxoSmithKline Plc. Il a obtenu son diplôme de premier cycle à l'université de Cambridge et un doctorat à l'Imperial College de Londres.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DBV TECHNOLOGIES SA
0,01% | 15/02/2023 | 6 837 ( 0,01% ) | 9 828 $ | 31/03/2024 |
Postes actifs de Ravi Rao
| Sociétés | Poste | Début |
|---|---|---|
| DBV TECHNOLOGIES | Director/Board Member | 19/05/2021 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 01/04/2024 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/04/2022 |
Anciens postes connus de Ravi Rao
| Sociétés | Poste | Fin |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | Chief Tech/Sci/R&D Officer | 01/01/2022 |
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 10/08/2020 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01/10/2019 |
| OXFORD BIOMEDICA PLC | Corporate Officer/Principal | - |
Formation de Ravi Rao
| Imperial College London | Doctorate Degree |
| University of Cambridge | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| DBV TECHNOLOGIES | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
